Literature DB >> 23389838

Amorphous solid dispersions of sulfonamide/Soluplus® and sulfonamide/PVP prepared by ball milling.

Vincent Caron1, Yun Hu, Lidia Tajber, Andrea Erxleben, Owen I Corrigan, Patrick McArdle, Anne Marie Healy.   

Abstract

The aim of this paper is to investigate the physicochemical properties of binary amorphous dispersions of poorly soluble sulfonamide/polymeric excipient prepared by ball milling. The sulfonamides selected were sulfathiazole (STZ), sulfadimidine (SDM), sulfamerazine (SMZ) and sulfadiazine (SDZ). The excipients were polyvinylpyrrolidone (PVP) and polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft co-polymer, commercially known as Soluplus®. Co-milled systems were characterised by powder X-ray diffraction and differential scanning calorimetry. PVP was shown to form amorphous dispersions over a wider composition range than Soluplus® for the four sulfonamides tested. Moreover, amorphous dispersions made with PVP were homogeneous [single glass transition (Tg)], while amorphous dispersions made from Soluplus® were heterogeneous (two Tgs). This behaviour is consistent with the fact that all the sulfonamides tested presented a lower solubility in Soluplus® than in PVP, as evidenced by Flory-Huggins parameters determined. Amorphous dispersions of SDM with Soluplus® could be produced even though SDM does not amorphise alone upon milling and Soluplus® presents Tg at a lower temperature than SDM. Amorphous dispersions of SMZ could be prepared with a lower excipient concentration compared to STZ, SDM and SDZ, which may reflect the one-dimensional H-bonding network in SMZ compared to the 2D or 3D H-bonding network found in the other sulfonamides. Stability tests (60% RH/25°C) revealed that dispersions made with Soluplus® remained dry and powdery compared to those made with PVP that formed a sticky paste in less than 2 weeks, indicating a possible advantage of using Soluplus® in terms of increased physical stability under high humidity storage conditions.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23389838      PMCID: PMC3581644          DOI: 10.1208/s12249-013-9931-7

Source DB:  PubMed          Journal:  AAPS PharmSciTech        ISSN: 1530-9932            Impact factor:   3.246


  28 in total

1.  Crystallization and transitions of sulfamerazine polymorphs.

Authors:  Geoff G Z Zhang; Chonghui Gu; Mark T Zell; R Todd Burkhardt; Eric J Munson; David J W Grant
Journal:  J Pharm Sci       Date:  2002-04       Impact factor: 3.534

Review 2.  Effects of mechanical processing on phase composition.

Authors:  Harry G Brittain
Journal:  J Pharm Sci       Date:  2002-07       Impact factor: 3.534

3.  Physicochemical characterization and drug-release properties of celecoxib hot-melt extruded glass solutions.

Authors:  Gavin P Andrews; Osama Abu-Diak; Febe Kusmanto; Peter Hornsby; Zhai Hui; David S Jones
Journal:  J Pharm Pharmacol       Date:  2010-11       Impact factor: 3.765

Review 4.  Solid state amorphization of pharmaceuticals.

Authors:  J F Willart; M Descamps
Journal:  Mol Pharm       Date:  2008 Nov-Dec       Impact factor: 4.939

5.  Solubility advantage of amorphous pharmaceuticals: I. A thermodynamic analysis.

Authors:  Sharad B Murdande; Michael J Pikal; Ravi M Shanker; Robin H Bogner
Journal:  J Pharm Sci       Date:  2010-03       Impact factor: 3.534

6.  Solubility advantage of amorphous pharmaceuticals: II. Application of quantitative thermodynamic relationships for prediction of solubility enhancement in structurally diverse insoluble pharmaceuticals.

Authors:  Sharad B Murdande; Michael J Pikal; Ravi M Shanker; Robin H Bogner
Journal:  Pharm Res       Date:  2010-09-22       Impact factor: 4.200

7.  A comparison of spray drying and milling in the production of amorphous dispersions of sulfathiazole/polyvinylpyrrolidone and sulfadimidine/polyvinylpyrrolidone.

Authors:  Vincent Caron; Lidia Tajber; Owen I Corrigan; Anne Marie Healy
Journal:  Mol Pharm       Date:  2011-03-03       Impact factor: 4.939

8.  Amorphous spray-dried hydroflumethiazide-polyvinylpyrrolidone systems: physiochemical properties.

Authors:  O I Corrigan; E M Holohan
Journal:  J Pharm Pharmacol       Date:  1984-04       Impact factor: 3.765

9.  Molecular mobility of amorphous pharmaceutical solids below their glass transition temperatures.

Authors:  B C Hancock; S L Shamblin; G Zografi
Journal:  Pharm Res       Date:  1995-06       Impact factor: 4.200

10.  Construction of drug-polymer thermodynamic phase diagrams using Flory-Huggins interaction theory: identifying the relevance of temperature and drug weight fraction to phase separation within solid dispersions.

Authors:  Yiwei Tian; Jonathan Booth; Elizabeth Meehan; David S Jones; Shu Li; Gavin P Andrews
Journal:  Mol Pharm       Date:  2012-12-07       Impact factor: 4.939

View more
  5 in total

1.  Polymer/Amorphous Salt Solid Dispersions of Ciprofloxacin.

Authors:  Hanah Mesallati; Lidia Tajber
Journal:  Pharm Res       Date:  2017-09-05       Impact factor: 4.200

2.  Physical Stability and Dissolution of Lumefantrine Amorphous Solid Dispersions Produced by Spray Anti-Solvent Precipitation.

Authors:  Sonal V Bhujbal; Vaibhav Pathak; Dmitry Y Zemlyanov; Lynne S Taylor; Qi Tony Zhou
Journal:  J Pharm Sci       Date:  2020-12-31       Impact factor: 3.534

3.  Enhancement of dissolution of atorvastatin through preparation of polymeric solid dispersions using supercritical fluid technology.

Authors:  Bashar Altaani; Rana Obaidat; Walaa Malkawi
Journal:  Res Pharm Sci       Date:  2020-05-11

4.  Improved dissolution of Kaempferia parviflora extract for oral administration by preparing solid dispersion via solvent evaporation.

Authors:  Yotsanan Weerapol; Sukannika Tubtimsri; Chaweewan Jansakul; Pornsak Sriamornsak
Journal:  Asian J Pharm Sci       Date:  2016-11-04       Impact factor: 6.598

5.  The Effect of Various Poly (N-vinylpyrrolidone) (PVP) Polymers on the Crystallization of Flutamide.

Authors:  Dawid Heczko; Barbara Hachuła; Paulina Maksym; Kamil Kamiński; Andrzej Zięba; Luiza Orszulak; Marian Paluch; Ewa Kamińska
Journal:  Pharmaceuticals (Basel)       Date:  2022-08-06
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.